Cuts at AstraZeneca

AstraZeneca announced that it will be eliminating 7,300 jobs, reports The Wall Street Journal. The Journal adds that these cuts, which are to be made by the end of 2014, will bring the company's total jobs cuts during the past five years to about 30,000. This round includes 2,200 cuts to R&D, 1,350 to manufacturing and operations, and 3,750 to administration and sales, and the closure of two neuroscience labs, one in Sweden and the other in Montreal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.